We at Verici Dx are excited to be attending the AST Cutting Edge of Transplantation conference from Thursday, February 22nd to Saturday, February 24th.
The overarching goal of the CEoT 2024 is to identify innovative technologies currently utilized to advance the medical field in general and describe how those could intersect with the practice of transplantation. Please do stop by our booth to learn what Tutivia™ is bringing to kidney transplant.
CMS finalises gapfill median rate at $2,650 per test
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that the Centers for Medicare & Medicaid Services (“CMS”) released the Clinical Laboratory Fee Schedule (“CLFS”) payment rate of $2,650 established through the “gapfill” process for both Tutivia™ (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava™ (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024.
Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.
Sara Barrington, Chief Executive Officer of Verici Dx, commented: “We are pleased that the pricing for both Tutivia™ and Clarava™ has been confirmed and finalised at the proposed rates. This is another important milestone in our strategy to develop and commercialise a complementary suite of ground-breaking products that offer end-to-end testing for kidney transplant patients and their clinicians.”
Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that its testing laboratory in Franklin, TN, has been accredited by the internationally recognised College of American Pathology (CAP) following the completion of an on-site audit. The Company, whose clinical laboratory is already CLIA certified, voluntarily sought the accreditation as part of its on-going commitment to maintaining best in class quality systems. CAP accreditation is a hallmark of quality and excellence in clinical laboratory services and adds to the Company’s existing portfolio of quality assurance awards and recognition.
In achieving the CAP accreditation requirements, which often exceed the standards from CLIA, FDA and OSHA, Verici Dx exhibits focus on excellence in patient care and laboratory safety. It also further demonstrates the laboratory’s ability to deliver reliable and accurate test results to support patient clinical management.
Patti Connolly, Chief Operating Officer at Verici Dx, said: “We are pleased that our highly skilled laboratory team
successfully achieved this accreditation with no deficiencies, findings, or recommendations identified during the
audit. This accomplishment affirms our commitment to operating at the highest standards that healthcare
providers, patients, and regulatory bodies expect.”